DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOMAVERT

« Back to Dashboard

All Clinical Trials for Somavert

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00151437	Canadian Pegvisomant Compassionate Study In Acromegalic Patients	Completed	Pfizer	Phase 4	2004-11-01	The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
NCT00476879	Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content	Completed	Aarhus University Hospital	N/A	2006-08-01	The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879	Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content	Completed	Pfizer	N/A	2006-08-01	The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879	Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content	Completed	University of Aarhus	N/A	2006-08-01	The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00552851	Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant	Unknown status	Pfizer	Phase 4	2006-06-01	The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.
NCT00552851	Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant	Unknown status	University of Wuerzburg	Phase 4	2006-06-01	The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.

Clinical Trial Conditions for Somavert

Condition Name

Condition Name for Somavert
Intervention	Trials
Acromegaly	9
Insulin Resistance	2
Prostatic Neoplasms	1
Colorectal Neoplasms	1

Condition MeSH

Condition MeSH for Somavert
Intervention	Trials
Acromegaly	9
Insulin Resistance	2
Breast Neoplasms	1
Endocrine System Diseases	1

Clinical Trial Locations for Somavert

Trials by Country

Trials by Country for Somavert
Location	Trials
United States	6
Canada	5
Denmark	3
Germany	2
Finland	1

Trials by US State

Trials by US State for Somavert
Location	Trials
California	3
Oregon	1
Tennessee	1
Minnesota	1

Clinical Trial Progress for Somavert

Clinical Trial Phase

Clinical Trial Phase for Somavert
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Somavert
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	3
Unknown status	2

Clinical Trial Sponsors for Somavert

Sponsor Name

Sponsor Name for Somavert
Sponsor	Trials
Pfizer	5
University of Aarhus	3
Aarhus University Hospital	3

Sponsor Type

Sponsor Type for Somavert
Sponsor	Trials
Other	17
Industry	7
NIH	2